Close Menu

NEW YORK (360Dx) – The European Union's Horizon 2020 program has awarded a €2.35 million ($2.7 million) grant for small- and medium-sized enterprises to Stockholm-based Elypta, which is developing a metabolism-based liquid biopsy platform for the detection and monitoring of cancers.

Elypta said it will use the Horizon 2020 Phase II grant to fund a multicenter trial aimed at validating its metabolism-based liquid biopsy platform for early detection of recurrent renal cell carcinoma (RCC), the most common form of kidney cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.